Funded Biotechnology Startups in New York
The 50 most recent biotechnology funding rounds in New York span January 2024 through November 2025, with disclosed deal sizes ranging from BioVaxys' $40K…
The 50 most recent biotechnology funding rounds in New York span January 2024 through November 2025, with disclosed deal sizes ranging from BioVaxys' $40K raise in April 2025 to Royalty Pharma's $1.5B in June 2024. Round classification is dominated by "Series Unknown" entries, though conventional tranches include Formation Bio's $372M Series D (June 2024), Metsera's $215M Series B (November 2024), three Series C rounds, and seven Seed deals.
Therapeutic concentration is visible across the dataset: CNS programs — Precision Neuroscience, Neurogene ($200M), MindMed ($75M), LB Pharmaceuticals ($75M Series C), and Gilgamesh Pharmaceuticals — account for a notable share, alongside oncology (Volastra Therapeutics, Nuvation Bio, TG Therapeutics), reproductive biotech (Gameto, Celmatix), and ophthalmology (Eyenovia, Oculogica). Click Therapeutics (Series C, March 2025) and Branching Minds (February 2024) represent the digital therapeutics end of the spectrum.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Royalty Pharma's $1.5B raise in June 2024 is the largest by a wide margin. Formation Bio's $372M Series D (June 2024), TG Therapeutics' $250M (August 2024), Metsera's $215M Series B (November 2024), and Neurogene's $200M (November 2024) are the next four largest disclosed amounts across the 50 rows shown.
What funding stages appear most frequently in New York biotech right now?
The majority of rows carry a "Series Unknown" classification, which limits stage-level filtering. Among identifiable conventional tranches: seven are Seed, three are Series B (including Metsera's $215M and Helaina's $45M), three are Series C, one is Series A (Levels, $10M), one is Series D (Formation Bio's $372M), and two are Pre-Seed.
Which therapeutic niches cluster most visibly in this New York biotech list?
CNS and neurology programs are the most recurring — Precision Neuroscience, Neurogene, MindMed, LB Pharmaceuticals, and Gilgamesh Pharmaceuticals all fall within that space. Oncology (Volastra Therapeutics, Nuvation Bio, TG Therapeutics), reproductive biotech (Gameto, Celmatix), and ophthalmology (Eyenovia, Oculogica) each form a secondary cluster.
How many companies in this list raised without disclosing an amount?
At least 10 of the 50 rows carry undisclosed amounts, including Precision Neuroscience (the most recent entry, November 2025), Click Therapeutics, Tonix Pharmaceuticals, Niura, and Traverse Biotech. Undisclosed rounds appear across all stages, from Seed to later-stage venture.
How active has New York biotech fundraising been in 2025 compared to 2024?
Thirteen of the 50 rows are from 2025 (February through November), with 37 from calendar year 2024. Notable 2025 closes include Nuvation Bio's $150M (March), Eyenovia's $50M (June), and Gameto's $44M Series C (August), indicating sustained deal flow into the current year.
What does the low end of round sizes look like in this dataset?
BioVaxys raised $40K in April 2025, the smallest disclosed amount in the dataset. Sharper Sense ($50K, June 2024), Definitive Diagnostics ($100K, May 2024), and OverT Bio ($120K, November 2024) are the other sub-$200K deals, all classified at Seed or Series Unknown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.